FC Strategy Focused on Specific Therapeutic Areas and Area Management
First written in FY2017-Q1. 19 of 26 entries say "Restated". Latest entry: 2026-03-25.
No other company in this theme has enough history to compare yet.
- 2026-03-25AdvancedBusiness Alliance
「With respiratory medicine, otolaryngology and urology designated as priority areas, we aim to contribute to the treatment of patients suffering from infectious diseases by adding the Product to our lineup under our franchise customer strategy of concentrating resources.」
A specific initiative was presented to add SIRTURO to the respiratory product lineup under the franchise customer strategy of concentrating resources in priority areas. The original canonical thread remains unchanged. - FY2025-H1RestatedAnnual report
「We conducted MR visits and meetings in line with the preferences of each medical institution and provided information through a combination of methods using digital promotion effectively, thereby supplementing and strengthening our sales capabilities and working to maximise the uptake of new drugs.」
Sales activities combining MR visits and meetings with digital promotion continue. - FY2024RestatedAnnual report
「We conducted MR visits and meetings in line with the preferences of each medical institution and provided information through a combination of methods using digital promotion effectively, thereby supplementing and strengthening our sales capabilities,」
Under the FC strategy and solution-based sales model, sales activities combining MR visits and meetings with digital promotion continue. - FY2024-Q3RestatedAnnual report
「We conducted MR visits and meetings in line with the preferences of each medical institution and provided information through a combination of methods using digital promotion effectively, thereby supplementing and strengthening our sales capabilities and working to accelerate the growth of new drugs.」
Under the FC strategy and solution-based sales model, sales activities combining MR visits and meetings with digital promotion continue. - FY2024-Q2AdvancedAnnual report
「While confirming the preferences of each medical institution, we expanded MR visits and meetings and provided information through a combination of methods using digital promotion effectively, thereby supplementing and strengthening our sales capabilities and working to accelerate the growth of new drugs.」
Under the solution-based sales model, MR visits and meetings were expanded and the combined provision of information with digital promotion was advanced. - FY2024-Q1AdvancedAnnual report
「To respond to this environment, Kyorin Pharmaceutical Co., Ltd. has made maximising the uptake of new drugs through solution-based sales (proposals for solving issues), based on its FC (franchise customer) strategy, a key strategy of its medium-term management plan and is actively pursuing these activities. During the cumulative first quarter of the fiscal year, as the COVID-19 pandemic entered a period of subsiding, we conducted MR visits and meetings in line with the preferences of each medical institution and provided information through the effective use of digital promotion, thereby supplementing and strengthening our sales capabilities and working to accelerate the growth of new drugs.」
While continuing its FC strategy and solution-based sales, the Company progressed to sales activities combining the resumption of MR visits and meetings with the effective use of digital promotion. - FY2023-Q1RestatedAnnual report
「While conducting MR visits and meetings in line with the preferences of each medical institution, we sought to supplement and strengthen our sales capabilities by providing information through a combination of digital channels and other methods,」
Under the FC strategy and solution-based sales model, sales activities combining visits and meetings with digital channels continue. - FY2022-Q3RestatedAnnual report
「As the COVID-19 pandemic continued, we refrained from MR visits and meetings in line with the preferences of each medical institution, while seeking to supplement and strengthen our sales capabilities by providing information through the combined, multifaceted use of digital channels in addition to conventional face-to-face meetings,」
Under the FC strategy and solution-based sales model, the use of digital channels to supplement the suspension of visits and meetings continues. - FY2022-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. is conducting its business while promoting its FC (franchise customer) strategy and making the shift to solution-based sales activities (proposals for solving issues) a key strategy of its current medium-term management plan.」
While maintaining the FC strategy for priority therapeutic areas, the shift to solution-based sales continues as a key strategy of the medium-term plan. - FY2022-Q1RestatedAnnual report
「Alongside advancing its FC (franchise customer) strategy, the Company has made the shift to solution-based sales activities (proposals for solving issues) a key strategy of its current medium-term management plan and is conducting its business accordingly.」
While maintaining the FC strategy for priority therapeutic areas, the shift to solution-based sales continues as a key strategy of the medium-term plan. - FY2021-Q3AdvancedAnnual report
「During the cumulative third quarter of the fiscal year, amid the impact of COVID-19, we actively provided information through the multifaceted use of digital channels as a support measure in addition to conventional meetings, seeking to supplement and strengthen our sales capabilities and promote MR activities aligned with the preferences of each medical institution,」
This has progressed to specific sales activities that use digital channels in a multifaceted manner in addition to the FC strategy and solution-based sales. - FY2021-Q2ReframedAnnual report
「As the market structure for prescription pharmaceuticals in Japan changes rapidly, Kyorin Pharmaceutical Co., Ltd. is conducting its business while promoting a shift to a solution-based sales style under its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
The direction of shifting to a solution-based sales style while maintaining the FC strategy for the 3 priority therapeutic areas has been clearly established. - FY2021-Q1ReframedAnnual report
「As the market structure for prescription pharmaceuticals in Japan changes rapidly, Kyorin Pharmaceutical Co., Ltd. is conducting its business through a group-wide sales organisation based on its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
While maintaining its FC strategy for the 3 priority therapeutic areas, its scope and application have expanded to a group-wide sales organisation. - FY2020-Q3RestatedAnnual report
「As the market structure for prescription pharmaceuticals in Japan changes rapidly as a result of drug pricing system reforms, Kyorin Pharmaceutical Co., Ltd. is developing sales activities through its own area management based on an FC (franchise customer) strategy focused on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
The concentration of sales activities on the 3 priority therapeutic areas and its own area management continue. - FY2020-Q1RestatedAnnual report
「We developed sales activities through our own area management based on an FC (franchise customer) strategy focused on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
The concentration of sales activities on the 3 priority therapeutic areas and its own area management continue. - FY2019RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. actively developed its own area management under its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology), and」
The concentration of sales activities on the 3 priority therapeutic areas and its own area management continue. - FY2019-Q3RestatedAnnual report
「As the market structure for prescription pharmaceuticals in Japan changes rapidly, Kyorin Pharmaceutical Co., Ltd. actively developed its own area management under its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
Sales activities centred on the concentration of sales activities on the 3 priority therapeutic areas and its own area management continue. - FY2019-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. actively developed its own area management under its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
Sales activities centred on the concentration of sales activities on the 3 priority therapeutic areas and area management continue. - FY2019-Q1RestatedAnnual report
「As the market structure for prescription pharmaceuticals in Japan changes rapidly with the progress of drug pricing system reforms, Kyorin Pharmaceutical Co., Ltd. developed sales activities centred on area management under its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
Sales activities centred on the concentration of sales activities on the 3 priority therapeutic areas and area management continue. - FY2018RestatedAnnual report
「As the structure of Japan's prescription pharmaceutical market changes rapidly, Kyorin Pharmaceutical Co., Ltd. is promoting the rebuilding of its sales organisation around area management under its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology),」
The rebuilding of the sales organisation around the concentration of sales activities on the 3 priority therapeutic areas and area management continues. - FY2018-Q3RestatedAnnual report
「As structural changes in Japan's prescription pharmaceutical market continue, Kyorin Pharmaceutical Co., Ltd. is advancing a sales strategy centred on area management, alongside the advancement of its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology).」
The concentration of sales activities on the 3 priority therapeutic areas and the sales strategy centred on area management continue. - FY2018-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. is advancing its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology), and implementing a sales strategy centred on area management, as the basis for」
The concentration of sales activities on the 3 priority therapeutic areas and the sales strategy centred on area management continue. - FY2017RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. is pursuing the advancement of its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology), and implementing a sales strategy centred on area management, under the policy of」
The concentration of sales activities on the 3 priority therapeutic areas and the sales strategy centred on area management continue. - FY2017-Q3RestatedAnnual report
「While pursuing active licensing activities, we aim to expand our product lineup in the priority therapeutic areas (respiratory medicine, otolaryngology and urology) and enhance our presence in these areas.」
The focus on the 3 priority therapeutic areas and the expansion of our product lineup and presence in these areas continue. - FY2017-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. is working to advance its FC (franchise customer) strategy, which concentrates sales activities on physicians and medical institutions in specific therapeutic areas (respiratory medicine, otolaryngology and urology), and to rebuild its sales organisation around area management.」
The concentration of sales activities on the 3 priority therapeutic areas and the rebuilding of the sales organisation around area management continue. - FY2017-Q1First statedAnnual report
「KYORIN Pharmaceutical Co.,Ltd. is working to advance its FC (Franchise Customer) strategy, which focuses sales activities on physicians and medical institutions in specific therapeutic areas—respiratory medicine, otolaryngology and urology—and this fiscal year is also restructuring its sales organization around area management.」
Sales efforts remain focused on priority therapeutic areas, while the sales organization is being restructured around area management in FY2016.